Digital seed amplification assay for TDP-43 aggregate quantification in CSF
Borberg, E.; Swank, Z. N.; Wickland Shearer, L.; Melkonian, A. V.; Rolando, J. C.; Walt, D. R.; Stern, A. M.
Show abstract
INTRODUCTIONDementia is commonly caused by underlying pathologies driven by misfolded protein aggregates. Although dementia subtypes have distinct mechanisms, overlapping symptoms make diagnosis without biomarkers difficult. Misdiagnosis has previously hindered drug development by enrolling patients non-specifically in trials. METHODSWe developed a digital Seed amplification assay (dSAA) that isolates individual aggregates in nanoliter compartments, enabling precise quantification of TDP-43 seeds in cerebrospinal fluid (CSF). RESULTSTesting 40 CSF samples from patients with genetic and sporadic FTLD-TDP, as well as healthy controls, we found elevated seed concentrations in FTLD-TDP patients that correlated with disease severity, demonstrating the potential of dSAA as a sensitive diagnostic tool. DISCUSSIONThis study demonstrates a new quantitative, high-sensitivity digital assay for TDP-43 seeds in CSF. The platforms single-aggregate resolution and low LOD establish a technical foundation for developing a diagnostic and monitoring tool for FTLD-TDP and other TDP-43-related diseases.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.